Amedisys Change In Cash vs End Period Cash Flow Analysis

AMED Stock

USD 90.64 0.48 0.53%

Amedisys financial indicator trend analysis is way more than just evaluating Amedisys prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amedisys is a good investment. Please check the relationship between Amedisys Change In Cash and its End Period Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Change In Cash vs End Period Cash Flow

Change In Cash vs End Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amedisys Change In Cash account and End Period Cash Flow. At this time, the significance of the direction appears to have strong relationship.

The correlation between Amedisys' Change In Cash and End Period Cash Flow is 0.73. Overlapping area represents the amount of variation of Change In Cash that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Amedisys, assuming nothing else is changed. The correlation between historical values of Amedisys' Change In Cash and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change In Cash of Amedisys are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Change In Cash i.e., Amedisys' Change In Cash and End Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.73

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Change In Cash

End Period Cash Flow

Most indicators from Amedisys' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amedisys current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.At present, Amedisys' Enterprise Value Over EBITDA is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 23.95, whereas Tax Provision is forecasted to decline to about 42.3 M.

	2021	2022	2023	2024 (projected)
Gross Profit	980.8M	962.8M	457.1M	447.4M
Total Revenue	2.2B	2.2B	2.2B	2.3B

Gross Profit Total Revenue

Amedisys fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock Total Equity	Common Stock
Total Assets		0.96	0.87	0.93	0.99	0.11	0.91	0.95	0.6	0.74	0.99	-0.36	0.74	0.95	0.35	0.96	0.29	0.9	-0.09	0.99	-0.16	0.95	0.91	0.37	0.52	0.53
Short Long Term Debt Total	0.96		0.83	0.81	0.93	0.1	0.98	0.95	0.53	0.61	0.97	-0.42	0.61	0.86	0.2	1.0	0.27	0.88	-0.25	0.97	-0.29	0.85	0.89	0.42	0.38	0.39
Other Current Liab	0.87	0.83		0.83	0.85	0.02	0.76	0.89	0.42	0.77	0.86	-0.19	0.77	0.76	0.06	0.84	0.01	0.86	-0.31	0.87	-0.2	0.78	0.82	0.19	0.25	0.25
Total Current Liabilities	0.93	0.81	0.83		0.91	0.16	0.74	0.82	0.58	0.76	0.9	-0.15	0.76	0.9	0.42	0.82	0.44	0.75	0.05	0.93	-0.1	0.93	0.81	0.16	0.57	0.58
Total Stockholder Equity	0.99	0.93	0.85	0.91		0.11	0.87	0.93	0.64	0.75	0.98	-0.38	0.75	0.97	0.41	0.93	0.23	0.91	-0.03	0.97	-0.11	0.95	0.9	0.38	0.57	0.58
Property Plant And Equipment Net	0.11	0.1	0.02	0.16	0.11		0.14	-0.06	0.15	-0.14	0.17	-0.03	-0.14	0.02	0.46	0.08	0.19	0.11	0.47	0.12	-0.24	0.02	0.12	0.03	0.46	0.46
Net Debt	0.91	0.98	0.76	0.74	0.87	0.14		0.91	0.55	0.46	0.93	-0.48	0.46	0.8	0.19	0.98	0.28	0.82	-0.27	0.92	-0.29	0.76	0.84	0.49	0.37	0.37
Retained Earnings	0.95	0.95	0.89	0.82	0.93	-0.06	0.91		0.47	0.68	0.94	-0.43	0.68	0.87	0.08	0.96	0.17	0.9	-0.39	0.94	-0.09	0.85	0.91	0.43	0.28	0.29
Accounts Payable	0.6	0.53	0.42	0.58	0.64	0.15	0.55	0.47		0.22	0.6	-0.43	0.22	0.69	0.74	0.53	0.11	0.36	0.37	0.58	0.04	0.56	0.37	0.43	0.78	0.78
Cash	0.74	0.61	0.77	0.76	0.75	-0.14	0.46	0.68	0.22		0.69	0.05	1.0	0.75	0.16	0.63	0.08	0.76	-0.02	0.71	-0.17	0.85	0.71	-0.05	0.29	0.3
Non Current Assets Total	0.99	0.97	0.86	0.9	0.98	0.17	0.93	0.94	0.6	0.69		-0.39	0.69	0.92	0.35	0.97	0.25	0.91	-0.1	0.99	-0.17	0.91	0.89	0.4	0.52	0.53
Non Currrent Assets Other	-0.36	-0.42	-0.19	-0.15	-0.38	-0.03	-0.48	-0.43	-0.43	0.05	-0.39		0.05	-0.31	-0.1	-0.43	-0.06	-0.4	0.16	-0.33	0.07	-0.22	-0.42	-1.0	-0.15	-0.15
Cash And Short Term Investments	0.74	0.61	0.77	0.76	0.75	-0.14	0.46	0.68	0.22	1.0	0.69	0.05		0.75	0.16	0.63	0.08	0.76	-0.02	0.71	-0.17	0.85	0.71	-0.05	0.29	0.3
Net Receivables	0.95	0.86	0.76	0.9	0.97	0.02	0.8	0.87	0.69	0.75	0.92	-0.31	0.75		0.48	0.86	0.27	0.8	0.06	0.92	-0.01	0.97	0.83	0.31	0.62	0.63
Common Stock Shares Outstanding	0.35	0.2	0.06	0.42	0.41	0.46	0.19	0.08	0.74	0.16	0.35	-0.1	0.16	0.48		0.2	0.2	0.16	0.83	0.3	0.13	0.41	0.09	0.11	0.96	0.96
Non Current Liabilities Total	0.96	1.0	0.84	0.82	0.93	0.08	0.98	0.96	0.53	0.63	0.97	-0.43	0.63	0.86	0.2		0.26	0.89	-0.25	0.97	-0.28	0.85	0.89	0.43	0.39	0.39
Inventory	0.29	0.27	0.01	0.44	0.23	0.19	0.28	0.17	0.11	0.08	0.25	-0.06	0.08	0.27	0.2	0.26		0.02	0.11	0.35	-0.16	0.35	0.3	0.06	0.24	0.25
Other Current Assets	0.9	0.88	0.86	0.75	0.91	0.11	0.82	0.9	0.36	0.76	0.91	-0.4	0.76	0.8	0.16	0.89	0.02		-0.2	0.87	-0.21	0.82	0.9	0.4	0.34	0.35
Other Stockholder Equity	-0.09	-0.25	-0.31	0.05	-0.03	0.47	-0.27	-0.39	0.37	-0.02	-0.1	0.16	-0.02	0.06	0.83	-0.25	0.11	-0.2		-0.14	-0.02	0.05	-0.25	-0.16	0.69	0.68
Total Liab	0.99	0.97	0.87	0.93	0.97	0.12	0.92	0.94	0.58	0.71	0.99	-0.33	0.71	0.92	0.3	0.97	0.35	0.87	-0.14		-0.21	0.93	0.9	0.33	0.48	0.49
Property Plant And Equipment Gross	-0.16	-0.29	-0.2	-0.1	-0.11	-0.24	-0.29	-0.09	0.04	-0.17	-0.17	0.07	-0.17	-0.01	0.13	-0.28	-0.16	-0.21	-0.02	-0.21		-0.1	-0.27	-0.07	0.1	0.09
Total Current Assets	0.95	0.85	0.78	0.93	0.95	0.02	0.76	0.85	0.56	0.85	0.91	-0.22	0.85	0.97	0.41	0.85	0.35	0.82	0.05	0.93	-0.1		0.85	0.22	0.56	0.57
Short Term Debt	0.91	0.89	0.82	0.81	0.9	0.12	0.84	0.91	0.37	0.71	0.89	-0.42	0.71	0.83	0.09	0.89	0.3	0.9	-0.25	0.9	-0.27	0.85		0.42	0.28	0.29
Current Deferred Revenue	0.37	0.42	0.19	0.16	0.38	0.03	0.49	0.43	0.43	-0.05	0.4	-1.0	-0.05	0.31	0.11	0.43	0.06	0.4	-0.16	0.33	-0.07	0.22	0.42		0.16	0.16
Common Stock Total Equity	0.52	0.38	0.25	0.57	0.57	0.46	0.37	0.28	0.78	0.29	0.52	-0.15	0.29	0.62	0.96	0.39	0.24	0.34	0.69	0.48	0.1	0.56	0.28	0.16		1.0
Common Stock	0.53	0.39	0.25	0.58	0.58	0.46	0.37	0.29	0.78	0.3	0.53	-0.15	0.3	0.63	0.96	0.39	0.25	0.35	0.68	0.49	0.09	0.57	0.29	0.16	1.0

Click cells to compare fundamentals

Amedisys Account Relationship Matchups

Amedisys fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Short Long Term Debt Total	326.1M	307.0M	545.6M	537.9M	487.2M	511.6M
Other Current Liab	(3.1M)	373.1M	291.8M	229.3M	356.6M	374.4M
Total Current Liabilities	326.9M	456.3M	374.3M	355.5M	473.7M	497.4M
Total Stockholder Equity	640.5M	809.2M	931.4M	1.1B	1.1B	1.1B
Property Plant And Equipment Net	112.9M	117.2M	119.7M	118.9M	130.8M	76.0M
Net Debt	295.8M	225.2M	502.9M	497.4M	360.8M	378.8M
Retained Earnings	246.4M	430.0M	639.1M	757.7M	747.9M	785.3M
Accounts Payable	31.3M	42.7M	38.2M	43.7M	28.2M	19.0M
Cash	30.3M	81.8M	42.7M	40.5M	126.5M	132.8M
Non Current Assets Total	912.2M	1.2B	1.5B	1.6B	1.6B	1.6B
Non Currrent Assets Other	18.9M	19M	19.9M	(20.4B)	19.0M	19.9M
Cash And Short Term Investments	30.3M	81.8M	42.7M	40.5M	126.5M	132.8M
Net Receivables	237.6M	255.1M	275.0M	296.8M	313.4M	329.0M
Common Stock Shares Outstanding	33.0M	33.3M	33.0M	32.7M	32.6M	23.4M
Liabilities And Stockholders Equity	1.3B	1.6B	1.9B	2.0B	2.1B	2.2B
Non Current Liabilities Total	294.3M	300.1M	506.4M	514.1M	466.7M	490.0M
Inventory	74.4M	11.8M	13.4M	25.2M	29.0M	30.5M
Other Current Assets	8.2M	25.0M	39.0M	51.6M	57.1M	60.0M
Other Stockholder Equity	394.0M	379.2M	292.3M	293.9M	318.6M	264.1M
Total Liab	621.2M	756.5M	880.6M	869.7M	940.4M	987.4M
Property Plant And Equipment Gross	28.1M	117.2M	216.6M	220.2M	368.6M	350.2M
Total Current Assets	350.6M	362.0M	356.7M	389.0M	496.9M	521.8M
Short Term Debt	37.7M	40.5M	44.2M	82.5M	88.9M	93.3M
Current Deferred Revenue	261.1M	60M	295.2M	20.4B	106.9M	101.5M
Other Liab	5.9M	33.6M	5.0M	25.2M	29.0M	30.5M
Other Assets	12K	174.6M	73.3M	39.3M	45.2M	47.5M
Long Term Debt	232.3M	204.5M	432.1M	419.4M	361.9M	380.0M
Treasury Stock	(251.2M)	(319.1M)	(435.9M)	(461.2M)	(415.1M)	(394.3M)
Property Plant Equipment	28.1M	23.7M	119.7M	16.0M	18.4M	17.5M
Good Will	658.5M	932.7M	1.2B	1.3B	1.2B	1.3B
Intangible Assets	64.7M	74.2M	111.2M	101.2M	102.7M	64.1M
Net Tangible Assets	(82.8M)	(197.6M)	(375.9M)	(337.0M)	(303.3M)	(288.1M)
Noncontrolling Interest In Consolidated Entity	1.1M	1.5M	45.0M	55M	63.3M	66.4M
Retained Earnings Total Equity	246.4M	430.0M	639.1M	757.7M	871.3M	914.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.35)

Earnings Share

2.52

Revenue Per Share

71.004

Quarterly Revenue Growth

0.057

Return On Assets

0.0627

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Change In Cash vs End Period Cash Flow Analysis

Change In Cash vs End Period Cash Flow

Change In Cash vs End Period Cash Flow Correlation Analysis

Correlation Coefficient

Change In Cash

End Period Cash Flow

Amedisys fundamental ratios Correlations

Amedisys Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amedisys fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Assets

Current Deferred Revenue	- 1.0	Non Currrent Assets Other
Non Currrent Assets Other	- 0.48	Net Debt
Non Current Liabilities Total	- 0.43	Non Currrent Assets Other
Non Currrent Assets Other	- 0.43	Accounts Payable
Non Currrent Assets Other	- 0.43	Retained Earnings
Short Term Debt	- 0.42	Non Currrent Assets Other